152 related articles for article (PubMed ID: 38831704)
21. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
22. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
23. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
[TBL] [Abstract][Full Text] [Related]
24. Which is the Ideal JAK Inhibitor for Alopecia Areata - Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway.
Sardana K; Bathula S; Khurana A
Indian Dermatol Online J; 2023; 14(4):465-474. PubMed ID: 37521227
[TBL] [Abstract][Full Text] [Related]
25. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
26. Nanostructured lipid carriers promote percutaneous absorption and hair follicle targeting of tofacitinib for treating alopecia areata.
Li Q; Wang Y; Guo Q; Cao J; Feng Y; Ke X
J Control Release; 2024 Jun; ():. PubMed ID: 38936744
[TBL] [Abstract][Full Text] [Related]
27. A cross-sectional study of the histopathology and immunology of alopecia areata: Unearthing the role of the Janus kinase-signal transducer and activator of transcription pathway.
Bansal A; Relhan V; Garg VK; Saran RK
Indian J Dermatol Venereol Leprol; 2019; 85(5):455-461. PubMed ID: 31031313
[TBL] [Abstract][Full Text] [Related]
28. Tofacitinib as a treatment of alopecia areata in adolescents.
Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
[TBL] [Abstract][Full Text] [Related]
29. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
30. Sisaipho alopecia areata treated with tofacitinib and oral minoxidil.
Talty R; Damsky W; King B
JAAD Case Rep; 2022 Nov; 29():41-42. PubMed ID: 36193241
[No Abstract] [Full Text] [Related]
31. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
Dincer D; Tanacan E; Kose Ozkan C
J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
[TBL] [Abstract][Full Text] [Related]
33. Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety.
Apalla Z; Zafiriou E; Zagkliverinou E; Roussaki-Schulze AV; Gidarokosta P; Ntavari N; Sakellaropoulou S; Boziou M; Emvalomati A; Kyrmanidou E; Lazaridou E
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810065
[TBL] [Abstract][Full Text] [Related]
34. Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data.
De Greef A; Thirion R; Ghislain PD; Baeck M
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2869-2877. PubMed ID: 37717224
[TBL] [Abstract][Full Text] [Related]
35. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
Oba MC; Askin O; Balci Ekmekci O; Serdaroglu S
J Cosmet Dermatol; 2021 Mar; 20(3):971-975. PubMed ID: 32808476
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
Asilian A; Mohammadian P; Shahmoradi Z
J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
[TBL] [Abstract][Full Text] [Related]
37. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib.
Lee JS; Huh CH; Kwon O; Yoon HS; Cho S; Park HS
J Dermatolog Treat; 2018 Dec; 29(8):819-822. PubMed ID: 29658800
[TBL] [Abstract][Full Text] [Related]
38. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
39. A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
Dillon KL
Clin Cosmet Investig Dermatol; 2021; 14():691-714. PubMed ID: 34211288
[TBL] [Abstract][Full Text] [Related]
40. Systematic review - alopecia areata and tofacitinib in paediatric patients.
Bandeira A; Albino-Teixeira A; Magina S
Cutan Ocul Toxicol; 2022 Jun; 41(2):194-201. PubMed ID: 35687530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
